Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Hughes

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 29, 2020
Retirement, GDPR, and word cloudsPhilip Hughes
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|November 4, 2004
Re: Improvement of neck and cheek laxity with a nonablative radiofrequency device: a lifting experiencePhilip Hughes
Clinical Medicine (London, England)|March 6, 2003
Senior house officers in medicine are still not getting adequate appraisalsKoshy Jacob, Philip Hughes
Leukemia Research and Treatment|December 6, 2012
Retinoid differentiation therapy for common types of acute myeloid leukemiaGeoffrey Brown, Philip Hughes
Journal of Pain Research|July 2, 2024
Transforming Growth Factor-β-Activated Kinase 1 (TAK1) Alleviates Inflammatory Joint Pain in Osteoarthritis and Gouty Arthritis Preclinical ModelsRobert Freeze, Philip Hughes, Timothy Haystead, et al.
Pharmacology Research & Perspectives|August 11, 2023
Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritisRobert Freeze, Kelly W Yang, Timothy Haystead, et al.
Leukemia Research and Treatment|December 22, 2012
Differentiation and cell survival of myeloid leukemia cellsGeorge P Studzinski, Geoffrey Brown, Michael Danilenko, et al.
ACS Chemical Biology|March 2, 2022
Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory ArthritisScott Scarneo, Philip Hughes, Robert Freeze, et al.
The Journal of Pain|April 4, 2026
Pharmacological inhibition of transforming growth factor-β activated kinase 1 (TAK1) prevents chemotherapy induced peripheral neuropathy (CIPN)Timothy Haystead, Denise Giuvelis, Robert Freeze, et al.
ACS Chemical Biology|May 18, 2026
Mapping the ATP-Binding Pockets of FLT3 and TAK1: A Structural Basis for Dual Inhibition by FLT3-Targeted TherapiesTimothy Haystead, Robert Freeze, Grace Liu, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 29, 2020
Retirement, GDPR, and word cloudsPhilip Hughes
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|November 4, 2004
Re: Improvement of neck and cheek laxity with a nonablative radiofrequency device: a lifting experiencePhilip Hughes
Clinical Medicine (London, England)|March 6, 2003
Senior house officers in medicine are still not getting adequate appraisalsKoshy Jacob, Philip Hughes
Leukemia Research and Treatment|December 6, 2012
Retinoid differentiation therapy for common types of acute myeloid leukemiaGeoffrey Brown, Philip Hughes
Journal of Pain Research|July 2, 2024
Transforming Growth Factor-β-Activated Kinase 1 (TAK1) Alleviates Inflammatory Joint Pain in Osteoarthritis and Gouty Arthritis Preclinical ModelsRobert Freeze, Philip Hughes, Timothy Haystead, et al.
Pharmacology Research & Perspectives|August 11, 2023
Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritisRobert Freeze, Kelly W Yang, Timothy Haystead, et al.
Leukemia Research and Treatment|December 22, 2012
Differentiation and cell survival of myeloid leukemia cellsGeorge P Studzinski, Geoffrey Brown, Michael Danilenko, et al.
ACS Chemical Biology|March 2, 2022
Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory ArthritisScott Scarneo, Philip Hughes, Robert Freeze, et al.
The Journal of Pain|April 4, 2026
Pharmacological inhibition of transforming growth factor-β activated kinase 1 (TAK1) prevents chemotherapy induced peripheral neuropathy (CIPN)Timothy Haystead, Denise Giuvelis, Robert Freeze, et al.
ACS Chemical Biology|May 18, 2026
Mapping the ATP-Binding Pockets of FLT3 and TAK1: A Structural Basis for Dual Inhibition by FLT3-Targeted TherapiesTimothy Haystead, Robert Freeze, Grace Liu, et al.
Pageof 4